Biotechne Corp (TECH)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

614 MCKINLEY PL N E MINNEAPOLIS, MN 55413

Techne and subsidiaries are engaged in the development, manufacture and sale of biotechnology products and hematology calibrators and controls. Co. has two segments: biotechnology and hematology. Co.'s biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products. Co., through its biotechnology segment, supplies proteins such as cytokines and related reagents. Co. also produces and markets enzymes and intracellular signaling reagents. Co. also markets one type of immunoassay kit under the trade name Quantikine. Co.'s hematology segment develops and manufactures hematology controls and calibrators for both impedance and laser type cell counters.

Data based on most recent fiscal year report
Market Cap5.487 Billion Shares Outstanding37.46 Million Avg Volume266.25 Thousand
1-Yr BETA vs S&P TR1.125 Current Ratio2.57 Quick Ratio2.12

Are you looking for this stock instead?

View SEC Filings from TECH instead.
Q2 2019 All Institutions Hedge Funds 1
To trade TECH now:
Filers who had this stock in their top 10: 5 1 (0.1%)
13F Filers holding this stock: 356 40 (4.13%)
Aggregate 13F shares on 06/30/2019: 34.883 Million 4.653 Million
Aggregate 13F shares on 03/31/2019: 35.041 Million 4.921 Million
Percent change: -0.45% -5.43%
Funds creating new positions: 50 13
Funds Adding to an existing position: 119 7
Funds closing out their position: 33 7
Funds reducing their position: 127 16
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding TECH (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

700 total shares from 3 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

41.4 Thousand total shares from 5 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HIGGINS JOHN L CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2019-09-19 2

KUMMETH CHARLES R. CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
136,056 2019-09-09 6

HIPPEL JAMES CHIEF FINANCIAL OFFICER

  • Officer
6,883 2019-08-19 3

EANSOR NORMAN DAVID SVP - NOVUS BIOLOGICALS

  • Officer
1,387 2019-08-19 3

FURLOW BRENDA S. SVP - GENERAL COUNSEL

  • Officer
3,203 2019-08-19 3

BAUMGARTNER ROBERT V

  • Director
8,726 2019-08-07 2

KELDERMAN KIM PRES. DIAGNOSTICS & GENOM

  • Officer
823 2019-08-07 2

VESSEY RUPERT

0 2019-07-01 2

SETH ALPNA

  • Director
8,713 2019-05-20 1

LUCAS ROGER C

  • Director
102,267 2019-03-05 0

STEER RANDOLPH C

4,226 2018-10-25 1

NUSSE ROELAND

5,226 2018-10-25 1

WIENS HAROLD J

4,726 2018-10-25 1

KEEGAN JOSEPH D

1,253 2018-10-25 1

MELSEN GREGORY J

  • Director
0 2018-10-01 0

DINARELLO CHARLES A

8,212 2018-08-08 0

BAZAN J. FERNANDO CHIEF TECHNICAL OFFICER

0 2017-10-26 0

GAVIN ROBERT M. SEN. VP PROTEIN PLATFORMS

1,667 2017-10-26 0

GOULD KEVIN S SVP CLINICAL CONTROLS

1,355 2017-10-26 0

HOLBROOK KAREN A

914 2017-09-06 0

VERONNEAU MARCEL SVP - CLINICAL CONTROLS

  • Officer
41,740 2015-08-07 0

OCONNELL HOWARD V

  • Director
72,000 2015-02-19 0

REAGAN KEVIN J SENIOR VP - BIOTECH

  • Officer
0 2014-12-05 0

OLAND THOMAS E CEO, PRESIDENT

  • Officer
  • Director
1,543,840 2011-11-30 0

HERBERT G A

  • Director
164,360 2008-10-23 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

KUMMETH CHARLES R. - Director - Officer CHIEF EXECUTIVE OFFICER by step-daughter

2019-09-09 P 100 $185.00 a 100 136,056.00 indirect

KUMMETH CHARLES R. - Director - Officer CHIEF EXECUTIVE OFFICER by step-son

2019-09-09 P 100 $185.00 a 100 136,056.00 indirect

EANSOR NORMAN DAVID - Officer SVP - NOVUS BIOLOGICALS

2019-08-19 M 2,287 d 0 1,387.00 direct

FURLOW BRENDA S. - Officer SVP - GENERAL COUNSEL

2019-08-19 M 1,759 d 0 3,203.00 direct

KUMMETH CHARLES R. - Director - Officer CHIEF EXECUTIVE OFFICER

2019-08-19 M 24,979 d 0 135,856.00 direct

HIPPEL JAMES - Officer CHIEF FINANCIAL OFFICER

2019-08-19 F 2,424 $197.57 d 6,883 6,883.00 direct

EANSOR NORMAN DAVID - Officer SVP - NOVUS BIOLOGICALS

2019-08-19 F 900 $197.57 d 1,387 1,387.00 direct

FURLOW BRENDA S. - Officer SVP - GENERAL COUNSEL

2019-08-19 F 745 $197.57 d 3,203 3,203.00 direct

KUMMETH CHARLES R. - Director - Officer CHIEF EXECUTIVE OFFICER

2019-08-19 M 24,979 a 135,856 135,856.00 direct

HIPPEL JAMES - Officer CHIEF FINANCIAL OFFICER

2019-08-19 M 4,925 a 9,307 6,883.00 direct

EANSOR NORMAN DAVID - Officer SVP - NOVUS BIOLOGICALS

2019-08-19 M 2,287 a 2,287 1,387.00 direct

FURLOW BRENDA S. - Officer SVP - GENERAL COUNSEL

2019-08-19 M 1,759 a 3,948 3,203.00 direct

HIPPEL JAMES - Officer CHIEF FINANCIAL OFFICER

2019-08-19 M 4,925 d 0 6,883.00 direct

KUMMETH CHARLES R. - Director - Officer CHIEF EXECUTIVE OFFICER

2019-08-13 M 7,410 $67.46 a 110,877 110,877.00 direct

KUMMETH CHARLES R. - Director - Officer CHIEF EXECUTIVE OFFICER

2019-08-13 M 7,410 d 57,590 110,877.00 direct

KELDERMAN KIM - Officer PRES. DIAGNOSTICS & GENOM

2019-08-07 A 2,363 a 2,363 823.00 direct

HIPPEL JAMES - Officer CHIEF FINANCIAL OFFICER

2019-08-07 A 3,938 a 3,938 4,382.00 direct

KUMMETH CHARLES R. - Director - Officer CHIEF EXECUTIVE OFFICER

2019-08-07 A 85,725 a 85,725 103,467.00 direct

FURLOW BRENDA S. - Officer SVP - GENERAL COUNSEL

2019-08-07 A 13,290 a 13,290 2,189.00 direct

EANSOR NORMAN DAVID - Officer SVP - NOVUS BIOLOGICALS

2019-08-07 A 21,265 a 21,265 0.00 direct

KELDERMAN KIM - Officer PRES. DIAGNOSTICS & GENOM

2019-08-07 A 15,948 a 15,948 823.00 direct

HIPPEL JAMES - Officer CHIEF FINANCIAL OFFICER

2019-08-07 A 26,581 a 26,581 4,382.00 direct

BAUMGARTNER ROBERT V - Director

2019-08-07 P 500 $191.06 a 8,726 8,726.00 direct

KUMMETH CHARLES R. - Director - Officer CHIEF EXECUTIVE OFFICER

2019-08-07 A 16,937 a 16,937 103,467.00 direct

FURLOW BRENDA S. - Officer SVP - GENERAL COUNSEL

2019-08-07 A 9,968 a 9,968 2,189.00 direct

EANSOR NORMAN DAVID - Officer SVP - NOVUS BIOLOGICALS

2019-08-07 A 15,948 a 15,948 0.00 direct

KELDERMAN KIM - Officer PRES. DIAGNOSTICS & GENOM

2019-08-07 A 11,961 a 11,961 823.00 direct

HIPPEL JAMES - Officer CHIEF FINANCIAL OFFICER

2019-08-07 A 19,936 a 19,936 4,382.00 direct

KUMMETH CHARLES R. - Director - Officer CHIEF EXECUTIVE OFFICER

2019-08-07 A 57,150 a 57,150 103,467.00 direct

KUMMETH CHARLES R. - Director - Officer CHIEF EXECUTIVE OFFICER

2019-08-07 A 11,291 a 103,467 103,467.00 direct

FURLOW BRENDA S. - Officer SVP - GENERAL COUNSEL

2019-08-07 A 1,969 a 1,969 2,189.00 direct

EANSOR NORMAN DAVID - Officer SVP - NOVUS BIOLOGICALS

2019-08-07 A 3,151 a 3,151 0.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments